• 1.

    Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:22952306. doi: 10.1056/NEJMoa1811744

  • 2.

    Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:21172128. doi: 10.1056/NEJMoa1504720

  • 3.

    Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380:347357. doi: 10.1056/NEJMoa1812389

  • 4.

    Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644657. doi: 10.1056/NEJMc1712572

  • 5.

    Pham PT, et al. Diabetes mellitus after solid organ transplantation. In: Endotext [Internet], edited by Feingold KR, et al. South Dartmouth, Massachusetts, MDText.com, Inc., 2000–2019 Apr 15. https://www.ncbi.nlm.nih.gov/books/NBK378977/

    • Search Google Scholar
    • Export Citation
  • 6.

    Halden TAS, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 2019; 42:10671074. doi: 10.2337/dc19-0093

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Mahling M, et al. Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus. Kidney Blood Press Res 2019; 44:984992. doi: 10.1159/000501854

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Rajasekeran H, et al. Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: A case series. Diabetes Care 2017; 40:e75e76. doi: 10.2337/dc17-0237

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    AlKindi F, et al. Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients. Transplant Proc 2020; 52:175178. doi: 10.1016/j.transproceed.2019.11.007

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Cehic MG, et al. Efficacy and safety of empagliflozin in the management of diabetes mellitus in heart transplant recipients. Transplant Direct 2019; 5:e450. doi: 10.1097/TXD.0000000000000885

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Heerspink HJL, et al. Nephrol Dial Transplant 2020; 35:274282. doi: 10.1093/ndt/gfz290

  • 12.

    Schwaiger E, et al. Empagliflozin in posttransplantation diabetes mellitus; a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant 2019; 19:907919. doi: 10.1111/ajt.15223

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Halden TS, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 2019; 42:10671074.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Hecking M, Jenssen T. Considerations for SGLT2 inhibitor use in post-transplantation diabetes. Nat Rev Nephrol 2019; 15:525526.

SGLT2 Inhibitors in Solid Organ Transplant Recipients with Type 2 Diabetes Mellitus

  • 1 Anju Yadav, MD, FASN, is an assistant professor of nephrology at Thomas Jefferson University Hospital, Philadelphia.
Restricted access
Save